在北美心脏外科手术出血中,血红蛋白复合缩剂会取代血吗?
Justyna Bartoszko1,2,3, Nadia Gabarin4, Kenichi Tanaka5
1Department of Anesthesia and Pain Management, University Health Network, Sinai Health, Women's College Hospital, University of Toronto.
Current opinion in anaesthesiology
|December 12, 2025
概括
四因子前激素复合缩物 (4F-PCC) 在心脏手术中治疗出血时,与血相比,显示出更好的疗效和安全性. 本综述强调了当前支持4F-PCC作为有益的治疗选择的证据.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 麻醉学 麻醉学
背景情况:
- 获得的凝血性出血是心脏外科手术中的一个重要问题.
- 血是传统的治疗方法,但四因子前激素复合缩物 (4F-PCC) 正在引起人们的兴趣.
- 4F-PCC与等离子体有不同的成分和潜在优势.
研究的目的:
- 审查目前关于4F-PCC在心脏外科手术中用于获得的凝固性出血的证据.
- 为了比较4F-PCC与血的疗效和安全性.
- 总结最近的临床试验和机制学研究的发现.
主要方法:
- 审查当前的临床证据,包括随机对照试验.
- 分析了支持4F-PCC在血液静止中的作用的机械数据.
- 从FARES-II试验和其他正在进行的研究中综合发现.
主要成果:
- 4F-PCC提供快速溶解和小的施用量,导致使用量增加.
- 临床试验证据表明,4F-PCC与血相比具有更好的静血疗效和安全性.
- 机理学数据支持4F-PCC能够使血栓生成正常化.
结论:
- 高质量的临床证据支持4F-PCC用于治疗心脏手术中的凝血性出血.
- 需要进一步研究性别和种族特异性疗效.
- 目前正在调查减少不良事件和在代表不足的程序中使用的机制.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Introduction to Hemostasis
13.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
13.0K
Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K
Cardiac Catheterization I: Pre-Procedure Overview
993
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
993


